During imatinib treatment, resistant cells can emerge in CML patients due to phenotypic shifting, resulting in the coexistence of imatinib‐sensitive BCR/Abl + leukaemic cells and an imatinib‐resistant subpopulation. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.